Clinical Trials Resource Center


April 29, 2002

Positive results were reported from a placebo-controlled study of AstraZeneca's Zomig (zolmitriptan) in women with migraine associated with menses. Subjects treated severe migraine attacks with 5.0 mg Zomig tablets, moderate attacks with 2.5 mg and mild attacks with 1.25 mg. At 30 minutes, 18% of subjects treated with Zomig achieved headache response (reduction from severe/mild pain to mild/none), compared to 14% of placebo-treated subjects. Additionally, headache response was 33% and 48% for the Zomig group, versus 23% and 27% for the placebo group, at one and two hours, respectively.

This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted.